vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and RESOURCES CONNECTION, INC. (RGP). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $117.7M, roughly 1.4× RESOURCES CONNECTION, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -19.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -11.8%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

RGP, formerly known as Resources Global Professionals, is the operating arm of Resources Connection, Inc.. The company provides consulting services in the areas of finance & accounting, information management, governance, risk & compliance (GRC), human capital, legal & regulatory, corporate advisory & restructuring, strategic communications, and supply chain management. As of fiscal year ending May 28, 2016, the company employed 3,283 professionals in 68 offices in 20 countries around the wor...

ESPR vs RGP — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.4× larger
ESPR
$168.4M
$117.7M
RGP
Growing faster (revenue YoY)
ESPR
ESPR
+162.9% gap
ESPR
143.7%
-19.2%
RGP
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-11.8%
RGP

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ESPR
ESPR
RGP
RGP
Revenue
$168.4M
$117.7M
Net Profit
$-12.7M
Gross Margin
37.1%
Operating Margin
50.6%
-10.3%
Net Margin
-10.8%
Revenue YoY
143.7%
-19.2%
Net Profit YoY
81.6%
EPS (diluted)
$0.32
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
RGP
RGP
Q4 25
$168.4M
$117.7M
Q3 25
$87.3M
$120.2M
Q2 25
$82.4M
$139.3M
Q1 25
$65.0M
$129.4M
Q4 24
$69.1M
$145.6M
Q3 24
$51.6M
$136.9M
Q2 24
$73.8M
$148.2M
Q1 24
$137.7M
$151.3M
Net Profit
ESPR
ESPR
RGP
RGP
Q4 25
$-12.7M
Q3 25
$-31.3M
$-2.4M
Q2 25
$-12.7M
$-73.3M
Q1 25
$-40.5M
$-44.1M
Q4 24
$-68.7M
Q3 24
$-29.5M
$-5.7M
Q2 24
$-61.9M
$10.5M
Q1 24
$61.0M
$2.5M
Gross Margin
ESPR
ESPR
RGP
RGP
Q4 25
37.1%
Q3 25
39.5%
Q2 25
40.2%
Q1 25
35.1%
Q4 24
38.5%
Q3 24
36.5%
Q2 24
40.2%
Q1 24
37.0%
Operating Margin
ESPR
ESPR
RGP
RGP
Q4 25
50.6%
-10.3%
Q3 25
-11.4%
-1.7%
Q2 25
8.6%
-47.0%
Q1 25
-34.0%
-38.4%
Q4 24
-6.4%
-52.7%
Q3 24
-31.0%
-3.5%
Q2 24
3.5%
7.6%
Q1 24
52.5%
2.8%
Net Margin
ESPR
ESPR
RGP
RGP
Q4 25
-10.8%
Q3 25
-35.9%
-2.0%
Q2 25
-15.4%
-52.6%
Q1 25
-62.2%
-34.0%
Q4 24
-47.2%
Q3 24
-57.2%
-4.2%
Q2 24
-83.9%
7.1%
Q1 24
44.3%
1.7%
EPS (diluted)
ESPR
ESPR
RGP
RGP
Q4 25
$0.32
$-0.38
Q3 25
$-0.16
$-0.07
Q2 25
$-0.06
$-2.21
Q1 25
$-0.21
$-1.34
Q4 24
$-0.14
$-2.08
Q3 24
$-0.15
$-0.17
Q2 24
$-0.33
$0.31
Q1 24
$0.34
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
RGP
RGP
Cash + ST InvestmentsLiquidity on hand
$167.9M
$89.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$194.6M
Total Assets
$465.9M
$289.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
RGP
RGP
Q4 25
$167.9M
$89.8M
Q3 25
$92.4M
$77.5M
Q2 25
$86.1M
$86.1M
Q1 25
$114.6M
$72.5M
Q4 24
$144.8M
$78.2M
Q3 24
$144.7M
$89.6M
Q2 24
$189.3M
$108.9M
Q1 24
$226.6M
$113.8M
Stockholders' Equity
ESPR
ESPR
RGP
RGP
Q4 25
$-302.0M
$194.6M
Q3 25
$-451.4M
$206.4M
Q2 25
$-433.5M
$207.1M
Q1 25
$-426.2M
$277.8M
Q4 24
$-388.7M
$325.7M
Q3 24
$-370.2M
$407.2M
Q2 24
$-344.2M
$418.8M
Q1 24
$-294.3M
$414.9M
Total Assets
ESPR
ESPR
RGP
RGP
Q4 25
$465.9M
$289.3M
Q3 25
$364.0M
$287.2M
Q2 25
$347.1M
$304.7M
Q1 25
$324.0M
$375.6M
Q4 24
$343.8M
$424.9M
Q3 24
$314.1M
$512.9M
Q2 24
$352.3M
$510.9M
Q1 24
$373.1M
$523.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
RGP
RGP
Operating Cash FlowLast quarter
$45.2M
$15.9M
Free Cash FlowOCF − Capex
$15.6M
FCF MarginFCF / Revenue
13.2%
Capex IntensityCapex / Revenue
0.0%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$24.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
RGP
RGP
Q4 25
$45.2M
$15.9M
Q3 25
$-4.3M
$-7.8M
Q2 25
$-31.4M
$16.8M
Q1 25
$-22.6M
$659.0K
Q4 24
$-35.0M
$1.8M
Q3 24
$-35.3M
$-309.0K
Q2 24
$-7.2M
$3.2M
Q1 24
$53.8M
$20.5M
Free Cash Flow
ESPR
ESPR
RGP
RGP
Q4 25
$15.6M
Q3 25
$-8.0M
Q2 25
$16.5M
Q1 25
$238.0K
Q4 24
$61.0K
Q3 24
$-35.5M
$-575.0K
Q2 24
$-7.3M
$3.0M
Q1 24
$53.8M
$20.4M
FCF Margin
ESPR
ESPR
RGP
RGP
Q4 25
13.2%
Q3 25
-6.6%
Q2 25
11.8%
Q1 25
0.2%
Q4 24
0.0%
Q3 24
-68.7%
-0.4%
Q2 24
-9.9%
2.1%
Q1 24
39.0%
13.5%
Capex Intensity
ESPR
ESPR
RGP
RGP
Q4 25
0.0%
0.3%
Q3 25
0.0%
0.1%
Q2 25
0.0%
0.2%
Q1 25
0.0%
0.3%
Q4 24
0.0%
1.2%
Q3 24
0.3%
0.2%
Q2 24
0.1%
0.1%
Q1 24
0.1%
0.1%
Cash Conversion
ESPR
ESPR
RGP
RGP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.30×
Q1 24
0.88×
8.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

RGP
RGP

US$93.7M80%
Non Us$24.0M20%

Related Comparisons